Overview

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

Status:
Not yet recruiting
Trial end date:
2023-09-12
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on LY3502970 in healthy overweight and obese participants. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study is conducted in two parts (part A and B) and will last up to 135 days including the screening period.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company